Labeled for this condition
Medicines for type 1 diabetes
9 medicines have an FDA label indicated for type 1 diabetes; 0 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for type 1 diabetes?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Insulin aspart | Novolog, Fiasp, Kirsty | none listed | $6.95 per mL 100 unit/mL vial | No | No current entry | 5 |
| Insulin lispro | Humalog, Lyumjev, Admelog | none listed | $10.19 per mL 100 unit/mL kwikpen | No | A presentation being discontinued | 4 |
| Insulin human | Humulin, Novolin, Afrezza | none listed | $4.26 per mL 70-30 vial | No | No current entry | 1 |
| Insulin glargine | Lantus, Toujeo, Semglee | none listed | $2.90 per mL 100 pen | No | A presentation being discontinued | 2 |
| Insulin degludec | Tresiba | none listed | $11.39 per mL 100 unit/mL pen | No | No current entry | 3 |
| Insulin glulisine | Apidra | none listed | $8.16 per mL 100 unit/mL vial | No | No current entry | 0 |
| Pramlintide | Symlinpen | none listed | n/a | Yes | A presentation being discontinued | 0 |
| Insulin detemir | Levemir | none listed | n/a | No | No current entry | 0 |
| Teplizumab | Tzield | none listed | n/a | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price